Antiretroviral (ARV) preexposure prophylaxis (PrEP) is highly effective in preventing HIV infection but requires laboratory monitoring. CDC recommends initial testing for renal function (serum creatinine), HIV, and hepatitis B infections; and ongoing testing for renal function, HIV, and sexually transmitted infections (STIs). To assess the uptake of these recommendations, we examined laboratory testing rates before and after PrEP initiation.
Using Marketscan, a commercial insurance claims database, we followed a cohort of HIV-uninfected persons aged 18-64 years who started PrEP during 2011-2014. Their first PrEP prescription date was the index date. The sample was limited to persons continuously enrolled in the health plan for ≥ 6 months pre-index. PrEP users were followed until the earliest occurrence of a) evidence of HIV infection, b) health plan disenrollment, or c) December 31, 2014. We estimated the incidence of laboratory testing at baseline (≤ 3 months pre-index) and conducted Kaplan-Meier analyses to estimate the cumulative incidence of follow-up tests. We used Cochrane-Armitage trend test to assess if testing rates varied by index year.
Our cohort of 2,140 new PrEP users were followed for a median duration of 142 days (interquartile range=79-237). Prior to PrEP initiation, 53% of the cohort was tested for HIV, 32% for hepatitis B, and 28% for serum creatinine. Among the 1,261 persons who were prescribed PrEP for ≥ 3 months, at 3 months after PrEP initiation, 30% had their first monitoring testing for HIV and 20% for creatinine; at 12 months, 62% had testing for HIV and 49% for creatinine. At 6 months after PrEP initiation, 46% of the cohort had testing for syphilis and 35% for chlamydia/gonorrhea. When stratified by index year, both baseline and follow-up testing rates increased significantly from 2011 to 2014 for all tests except for creatinine. For example, the rate of baseline HIV testing was 26% in 2011 and 54% in 2014 (Ptrend < 0.001).
For these PrEP users, laboratory testing was less frequent than recommended, although most of the testing rates improved as the number of PrEP prescriptions increased. Monitoring for HIV infection is crucial for early detection and to avoid ARV drug resistance. Other tests are important to detect possible renal toxicity of PrEP and incident STIs. There are opportunities to increase laboratory testing for PrEP users, especially for serum creatinine. Our analysis provides estimates for future evaluation.